JPRN-UMIN000000913已完成2 期
Randomized phase II trial of Carboplatin/Gemcitabine versus Cisplatin/Gemcitabine for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer - Randomized phase II trial of CBDCA/GEM versus CDDP/GEM for the patient with completely resected pathological stage IB-IIIA of Non Small Cell Lung Cancer
Hokkaido Lung Cancer Clinical Study Group0 个研究点目标入组 102 人开始时间: 2007年11月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. sever infection 2. uncontrolled Diabetes Mellitus and hypertension, unstable angina or Myocardial Infarction within 6 months 3. apparent interstitial pneumonitis at chest rentogenogram 4. Uncontrollable pleural effusion 5. multiple lung cancer or other-type cancer within 5 years 6. History of severe hypersensitivity 7. Pregnant or expecting woman
研究者
相似试验
已完成
不适用
Randomized phase II study of carboplatin / gemcitabine versus vinorelbine / gemcitabine in patients with advanced non-small cell lung cancerStage IIIb/IV NSCLCJPRN-C000000110West Japan Oncology Group120
已完成
不适用
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumCancerISRCTN88259320School of Medicine, Zhejiang University (China)39
进行中（未招募）
1 期
A trial of carboplatin and gemcitabine +/- vandetanib to treat patients with advanced bladder cancer who can't be treated with cisplatiTransitional cell carcinoma of urothelium (upper or lower urinary tract). Cancers with other pathologies are permitted, provided that the dominant morphology is transitional cell carcinoma.EUCTR2009-010140-33-GBCardiff University82
未知
不适用
Phase II study of carboplatin-gemcitabine combination chemotherapy in elderly patients with advanced non–small cell lung cancerJPRN-C000000112Kumamoto University School of Medicine55
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105